Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary
April 28, 2022
Earnings Call Speaker Segments
Peter Dannenbaum
executiveThanks, Grace, and good morning. It's a pleasure to welcome everyone to Merck's conference call for the first quarter of 2022. Joining us on today's call are Rob Davis, our President and Chief Executive Officer; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Li, President of Merck Research Labs. Before we begin, there are a few things I want to flag. In our GAAP results, you'll notice certain items, including charges tied to acquisitions, costs from restructuring, and some other items as well. Please be aware that these have been excluded from our non-GAAP results, and a reconciliation is provided in our press release. I also want to remind everyone that certain statements we make today could be viewed as forward-looking statements under the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These statements reflect Merck management's current beliefs and carry significant risks and uncertainties. Should our underlying assumptions turn out to be inaccurate, or should uncertainties come to pass, actual results could differ materially from those described in the forward-looking statements. Our SEC filings, including Item 1A in the 2021 10-K, lay out certain risk factors and cautionary statements that might cause the company's actual results to differ materially from those projected in any forward-looking statements we make this morning. Merck assumes no obligation to publicly update any forward-looking statements. A slide presentation will accompany our speakers' prepared remarks during today's call. The presentation, today's earnings release, and our SEC filings are all available in the Investor Relations section of Merck's website; with that, I'll hand the call over to Rob.
Rob Davis
executiveThanks, Peter. Good morning, everyone, and I appreciate you being on today's call. First, I want to take a moment to address the crisis that continues to unfold in Ukraine. We hope for a peaceful and immediate end to Russia's invasion of that country, and we stand with the Ukrainian people in support, recognizing the terrible tragedy this represents. Merck is doing everything possible to safeguard our employees' health and safety while making sure essential medicines and vaccines keep reaching patients. We are also committing substantial resources through various channels to tackle the humanitarian crisis there. Now, on to our business. In Q1, we continued to execute against our top strategic objectives. The robust commercial momentum we carried out of 2021 remains intact, reflected in healthy increases on both revenue and earnings. We also achieved meaningful clinical milestones across our research pipeline and wrapped up a smooth integration of Acceleron. Now, looking at our performance, 2022 is off to a very good start, marked by very strong growth in both revenue and earnings. On the commercial front, we continue to perform well across many of our major growth drivers, especially KEYTRUDA, GARDASIL, and Animal Health. The trends we see point to solid underlying demand for our de-risked innovative portfolio, and they highlight just how essential our science-led strategy is. LAGEVRIO, our COVID-19 antiviral therapy, also made a substantial contribution. Even setting aside those sales, revenue was up a solid 19% year over year. As for LAGEVRIO, we've accelerated access around the world, and it has become a key resource that patients and health care providers rely on to fight the pandemic. Following the December emergency use authorization, we've shipped about 6.4 million courses to more than 30 countries. You can see this momentum in the 2022 guidance we've updated, which captures our outlook for another year of robust growth and continued business momentum. Within oncology, we're benefiting as new and significant indications keep rolling out, including in earlier lines of therapy. Worldwide interest in GARDASIL continues to be robust, and that momentum will be boosted by additional supply resulting from the significant capital we are deploying to scale up production. Meanwhile, our Animal Health division is still set up to outpace the broader market in terms of growth. Looking further ahead, we have confidence in our ability to keep generating solid top-line gains and widening operating margins all the way through 2025. As we prepare for the period when KEYTRUDA loses exclusivity, we keep reinforcing the advantages already at our disposal and layering more on top of them so we can achieve growth over the long haul. Within oncology, we stay dedicated to extending the cornerstone role we have built with KEYTRUDA, and our goal is to broaden our footprint in this vital therapeutic category while securing a lasting leadership role. Beyond that, we'll keep making the most of what we view as our long-term growth engines — GARDASIL, our pneumococcal lineup and Animal Health — by relying on our track record of commercial execution. In terms of what's already ours, BD remains at the very top of the list. We keep a sharp eye out for the best innovation available externally, and whenever great science lines up with strong value, we'll move with the right degree of boldness. Our track record in business development is a good one, though we know additional effort is needed. We also believe our setup lets us shift capital quickly toward the right strategic assets once they present themselves. Last, we'll keep pushing our extensive pipeline forward in major therapeutic areas so we can bring patients innovations that matter medically. We've made key moves to give greater visibility into the chances we see within our portfolio and our business, such as through 2 recent investor events. Earlier this month, we gave a thorough look at our expanding cardiovascular portfolio and pipeline. Here at Merck, our efforts go where needs are largest and where we have the strongest chance to improve patients' lives, covering heart failure, pulmonary arterial hypertension, thrombosis and atherosclerosis. Across our CV pipeline, we've made substantial headway, and we believe our broad, distinctive portfolio could have a real impact on patients' lives — including no fewer than 8 potential new approvals between now and 2030. We're confident that these essential breakthroughs may act as significant engines of growth for Merck far into the coming decade. Also, in February we hosted our inaugural ESG event, highlighting what we're doing across our 4 priority areas: access to health, employees, environmental sustainability and ethics and values. That ESG effort stems from the values of our company, and going forward we expect to continue Merck's tradition of operating responsibly. Before I close, I'd like to take a moment to recognize Dr. Roy Baynes has told us he intends to retire now that he's spent eight years with Merck. Merck became a leading oncology company in large part because of Roy, above all through his work heading up development of KEYTRUDA. Our best wishes go with Roy for whatever comes next, and we have no doubt that the team and program he leaves behind are in excellent shape. I'm pleased to share that Dr. Eliav Barr will step into Roy's role. Eliav's credentials include not only extensive experience gained across several research positions during more than 20 years with Merck, but also an unwavering commitment to patients that reflects Merck's mission of saving and improving lives. In closing, we entered 2022 with strong momentum in our operations, and I sincerely thank all of our team members worldwide for the commitment and attention they continue to show. We remain assured in our fundamental approach, our prospects for expansion, and our ability to deliver meaningful benefits to patients as well as returns for shareholders far into the years ahead. On that note, I'll turn things over to Caroline.
Caroline Litchfield
executiveThank you, Rob, and good morning to everyone. As Rob pointed out, 2022 has gotten off to an outstanding start, with remarkable results on both the top and bottom lines. What these figures show is that placing science and innovation at the heart of what we do, powered by superb execution from our committed team members around the world, is generating value for patients, customers and investors alike. Company-wide revenues came in at $15.9 billion, which represents a 50% jump. LAGEVRIO accounted for $3.2 billion of that revenue. Once you set LAGEVRIO aside, the base business posted extremely robust growth of 19%. Everything else I say will be presented on an ex-exchange basis. Momentum remained solid in our human health segment. With LAGEVRIO excluded, human health expanded 21%, propelled mainly by our key pillars along with the diminishing effects of the pandemic. Our Animal Health segment likewise outperformed the market, with sales up 9%, fueled by gains in both the companion animals and livestock categories. Let me now discuss how our key brands performed in the first quarter. Within oncology, KEYTRUDA rose 27% to reach $4.8 billion, a reflection of sustained strong global demand and growth into additional indications; here in the U.S., KEYTRUDA keeps showing robust gains across every major tumor type and is gaining from recent approvals in earlier-stage cancers, such as triple-negative breast, renal cell carcinoma and melanoma. At present, KEYTRUDA holds approval for treating 5 indications in earlier-stage cancers, and the promising data from KEYNOTE-091 has us enthusiastic about the chance to move into adjuvant lung cancer. Our confidence remains firm that KEYTRUDA's strong clinical profile, together with how familiar and experienced physicians are with it, will pave the way for broader use and greater patient benefit in early-stage disease; when it comes to the metastatic setting, KEYTRUDA holds onto its leading spot in non-small cell lung cancer, bringing in 8 of every 10 eligible new patients. Beyond the U.S., lung cancer along with the continuing launches in head and neck cancer and renal cell carcinoma keep powering KEYTRUDA's growth. Lynparza continues to be the top-selling PARP inhibitor on the market. Alliance revenue for it climbed 20%, lifted by adoption in metastatic breast cancer. The broader opportunity in early-stage breast cancer also has us excited, now that the FDA recently approved it based on the OlympiA study. On top of that, we hope to eventually serve a wide prostate population, drawing on the PROpel study. Lenvima alliance revenue similarly posted very robust growth, propelled by adoption after the launches of KEYNOTE-581 in advanced renal cell carcinoma and KEYNOTE-775 in metastatic endometrial cancer, and across each of those tumor types we are seeing promising shifts in new patient share. Lenvima's growth was further helped by stronger demand in hepatocellular carcinoma within China plus some onetime items. The launch of WELIREG for patients with certain VHL-associated tumors is another source of excitement for us. WELIREG keeps drawing substantial interest from scientific leaders, providers and patients. Even though its launch is still at an early stage, WELIREG has seen robust adoption, offering a therapeutic choice for the considerable unmet need these patients face. We're exploring ways that it could eventually reach additional RCC uses down the road. Once more, our vaccines lineup turned in outstanding results, with GARDASIL out in front, climbing 60% to $1.5 billion. Beyond the U.S., the growth came largely from solid underlying demand in important markets, especially China, plus more supply. Stateside, the gain reflected when CDC purchases landed. Demand worldwide for GARDASIL stays strong, backed by solid clinical and real-world evidence and by work to build awareness of GARDASIL as a vaccine that helps prevent certain HPV-related cancers in women and men alike. Within our hospital acute care portfolio, BRIDION posted a 20% sales increase, fueled by the continued rebound in surgical procedures over the quarter and by the sustained strong position of the neuromuscular blockade reversal agent category. Another quarter of solid growth came from our Animal Health business, where sales rose 9%. Companion animal sales were up 13%, lifted by worldwide demand in parasiticides, covering the BRAVECTO product line and vaccines too. Livestock sales climbed 7% on stronger demand in ruminants and poultry. Now I'll take you through the rest of our P&L, and everything I say will be on a non-GAAP basis. Gross margin came in at 70.7%, down 5.9 percentage points, mostly because of higher LAGEVRIO sales. Keep in mind that we split LAGEVRIO profits evenly with our partner Ridgeback, and that shows up in cost of sales, pulling our gross margin percentage down. This quarter's gross margin also captures the positive effect of product mix, balanced against greater manufacturing costs. Operating expenses rose 7% to $4.8 billion as we keep investing carefully behind our growth drivers and pipeline. Other expense came to roughly $140 million. Our tax rate stood at 14%. All told, we earned $2.14 per share. Now let's turn to our 2022 non-GAAP guidance. Keep in mind that, at the SEC's request, some companies in our sector, ours included, have altered their non-GAAP reporting. We will stop excluding sizable expenses for upfront and milestone payments tied to collaborations and licensing agreements, along with transactions treated as asset acquisitions, from non-GAAP results. Because of that, $1.7 billion in R&D charges, mostly tied to the Pandion acquisition, are now part of our recast 2021 non-GAAP results. That pushed R&D expense up by $1.7 billion and cut non-GAAP EPS by $0.65. The first quarters of 2021 and 2022 saw no impact. Our 2022 guidance assumes no major transactions of the kind that would previously have been left out of non-GAAP. So this may shift in coming quarters should we pursue business development, which is a strategic priority. The fundamental strength of our business lets us lift and tighten our full year guidance. We now anticipate revenue ranging from $56.9 billion to $58.1 billion, which means growth of 17% to 19%, or 11% to 12% once you exclude LAGEVRIO and the foreign exchange effect. When we look at the projected hit from foreign exchange, that figure includes an added headwind of roughly $200 million based on rates from mid-April, which brings the negative effect across the full year to slightly more than 2%. Our gross margin outlook is being raised to a range of 74% to 74.5%. For operating expenses, we're looking at $20.3 billion to $21.3 billion. Sitting at the midpoint, that aligns with what our earlier guidance implied; for other expense, we're expecting about $350 million. Our assumption for the full year tax rate sits between 13.5% and 14.5%, reflecting a rise in estimated U.S. taxes owed on foreign income. We're assuming 2.53 billion shares outstanding. Putting all of this together, our expected EPS range has been lifted to $7.24 to $7.36, which reflects pull-through of the operational strength from our key pillars along with operating expense leverage, partly offset by a modest trimming of the high end of our LAGEVRIO sales assumption, the higher tax rate, and an added 1% headwind from foreign exchange at mid-April rates. As you work through your models, here are a few things to keep in mind. Starting with LAGEVRIO; we're tightening our full year guidance range to $5 billion to $5.5 billion. Supply and purchase agreements have been signed for roughly 10 million courses of therapy. Since receiving authorization, we've delivered 6.4 million courses of therapy, with 5 million of those coming in the first quarter. Roughly half of the remaining full year revenue from LAGEVRIO should land in the second quarter; for GARDASIL, we still anticipate robust annual growth, particularly in markets outside the U.S., China included. Lastly, just a reminder that our other revenue line has a number of components, among them supply sales to Organon, which we started recording once the spin-off closed last year, and to Johnson & Johnson for its COVID vaccine. Revenue hedge and royalties are in there as well. Other revenue in the first quarter also got a boost of about $100 million from receipts tied to out-licensing agreements. Our priorities for capital allocation haven't changed. First, we'll keep prioritizing investments in our business and pipeline to drive near- and long-term growth. We'll stay appropriately aggressive when it comes to augmenting our internal pipeline through strategic business development, and we plan to chase additional value-enhancing opportunities. We're still committed to the dividend, with the aim of raising it over time. Where we have excess cash, we'll return it to shareholders via share repurchases. In closing, we have strong confidence in our business's growth, fueled by worldwide demand for our innovative medicines and vaccines; we're in a position of financial and operational strength, and by continuing to execute, we'll deliver value to patients and our shareholders well into the future; with that, I'd like to hand the call over to Dean.
Dean Li
executiveThank you, Caroline. It's a pleasure to be with you and share where we stand on our efforts. During Q1, we kept showing momentum in our pipeline; we moved forward across a number of therapeutic areas, from oncology — both advanced and earlier-stage cancer — to cardiovascular disease and vaccines. I'll also give you an update on LAGEVRIO. Within oncology, we keep strengthening our position and carrying out our strategy to broaden, deepen and lengthen the benefits we bring to patients while diversifying what we do in cancer; over the past quarter, we hit milestones spanning several tumor types and various disease stages. Specifically, our therapeutic reach keeps expanding into earlier disease phases, and we currently have 6 FDA approvals in that space — 5 belonging to KEYTRUDA and 1 to Lynparza. During the European Society for Medical Oncology Virtual Plenary session held last month, findings were shared from the PEARLS study, also known as KEYNOTE-091, which looks at KEYTRUDA as adjuvant therapy for patients following surgical resection who have stage IB to IIIA non-small cell lung cancer. In an interim analysis, the drug produced a significant disease-free survival improvement across all-comers, which counts as one of the trial's dual primary endpoints. One of the dual primary goals, disease-free survival among patients with tumors showing elevated PD-L1 expression, is still being evaluated by the trial; at the scheduled interim analysis, that endpoint had not reached statistical significance. For KEYTRUDA's potential in this adjuvant setting, these newer results offer a compelling indication of benefit. Several further trials are underway in earlier-stage non-small cell lung cancer: KEYNOTE-671, examining neoadjuvant plus adjuvant treatment in resectable stage II, IIIA and IIIB disease; KEYNOTE-867, assessing stereotactic body radiotherapy with or without KEYTRUDA among adults who have unresected stage 1 HER2 disease; and KEYLYNK-012, in which the combination of KEYTRUDA and Lynparza is being investigated in stage III disease. After KEYTRUDA received approval for use as adjuvant therapy in patients aged 12 and up who have stage IIB or IIC melanoma and have undergone complete resection, based on KEYNOTE-716, we shared that a prespecified interim analysis found the trial had also achieved its secondary endpoint of distant metastasis-free survival, along with ongoing gains in recurrence-free survival relative to placebo. Findings from KEYNOTE-716 strengthen the case for KEYTRUDA as adjuvant treatment in suitable stage IIB and IIC patients after surgery, aiding in the prevention of disease recurrence. Also, turning to earlier stages of disease, we shared news with AstraZeneca that the FDA cleared Lynparza for adjuvant use in patients who have germline BRCA mutations and HER2-negative, high-risk early breast cancer and who had prior chemotherapy, given either before or after surgery, drawing on the OlympiA trial. In addition, within women's cancers, KEYTRUDA won FDA approval to treat patients whose advanced endometrial carcinoma is microsatellite instability-high or mismatch repair-deficient, supported by fresh findings from KEYNOTE-158. So this approval becomes the fourth one for KEYTRUDA in gynecologic cancers, and it's also the fifth to come out of KEYNOTE-158 — a novel study built to look at how predictive tumor biomarkers perform in patients who receive KEYTRUDA for advanced solid tumors. Moving on to prostate cancer. Together with AstraZeneca, we presented positive data at the American Society of Clinical Oncology Genitourinary Cancers Symposium from PROpel, which is assessing Lynparza plus abiraterone as a first-line option for people who have metastatic castrate-resistant prostate cancer, both with and without mutations in a set of homologous recombination or therapy. In a planned interim analysis, the findings demonstrated better radiographic progression-free survival compared with the standard of care; those early data likewise pointed to a trend of improved overall survival. The study will keep evaluating this key secondary endpoint, and we intend to talk with health authorities about the results, with the goal of getting this important choice to the right patients. Prostate cancer reflects a considerable unmet need, and we keep picking up valuable understanding of the tumor's biology. We're eager to make a difference for those with late-stage disease. Last month, we said we were discontinuing KEYLYNK-010, which was looking at KEYTRUDA combined with Lynparza for metastatic castrate-resistant prostate cancer. During an interim look at that trial, there was no evidence that it outperformed abiraterone or enzalutamide on overall survival or radiographic progression-free survival. Attention in metastatic castrate-resistant prostate cancer is now shifting toward KEYNOTE-921, which is studying KEYTRUDA together with chemotherapy, and KEYNOTE-641, which is evaluating KEYTRUDA alongside enzalutamide. Outside the U.S., we continue to carry out our regulatory strategy. Among the key developments are favorable CHMP opinions in Europe for cervical, MSI-high and early-stage breast cancer, as well as approvals in Japan for KEYTRUDA combined with Lenvima in advanced renal cell carcinoma. Finally, to coincide with ASCO, we intend to host an investor event in Chicago in early June. During our cardiovascular investor event not long ago, we showcased a growing lineup of programs targeting multiple conditions, including atherosclerosis, heart failure, pulmonary arterial hypertension and thrombosis. Having wrapped up the Acceleron Pharma purchase, we're progressing well in advancing sotatercept, a soluble activin receptor type IIA fusion protein that could be first-in-class. Enrollment for the STELLAR trial has just been completed sooner than planned. Among 4 ongoing Phase III studies evaluating sotatercept, STELLAR is the initial one. This pace reflects investigators' excitement about this novel investigational mechanism. During this earnings call, we want to highlight that the 2022 heart failure management guideline from the American Heart Association, the American College of Cardiology, and the Heart Failure Society of America has, for the very first time, included Verquvo—a product we develop alongside our partner, Bayer—as a Class IIB recommendation for stage C heart failure with reduced ejection fraction. In that guideline, the sGC submechanism represented by Verquvo is specifically noted, along with the potential benefits that come from stimulating soluble guanylate cyclase and increasing cyclic GMP. Based on the evidence from the groundbreaking VICTORIA trial, Verquvo is the first therapy that was both designed specifically for and approved to treat patients experiencing worsening heart failure, and among the updated guidelines, it is the only treatment given an endorsement for that patient population. Through our continuing VICTOR study, we aim to broaden the existing evidence base by assessing Verquvo among people who have chronic heart failure with reduced ejection fraction and who have not had a recent worsening heart failure episode. With no fewer than 8 possible approvals anticipated by 2030 — among them Verquvo, stable heart failure, and sotatercept, plus our pipeline candidates such as an inhaled soluble guanylate cyclase stimulator, a Factor XI inhibitor, and an oral PCSK9 inhibitor — Merck holds a distinctive position to substantially change how cardiovascular disease patients are treated. Turning to COVID-19 and LAGEVRIO: as the pandemic shifts, regional spikes in infection rates keep occurring alongside the arrival of new COVID-19 variants; certain of these strains now resist particular monoclonal antibody regimens and seem capable of dodging some vaccine protection, which underscores how vital testing is and how important it is that an antiviral choice remains available. During the latest European Congress of Clinical Microbiology and Infectious Diseases, we shared Phase III virology outcomes data for MOVe-OUT, which strengthens the expanding evidence supporting LAGEVRIO's antiviral characteristics.
Dean Li
executiveTwo trials are currently underway: PANORAMIC, which is assessing novel antivirals for early treatment and is sponsored by the University of Oxford with funding from the U.K. government, and MOVe-AHEAD, which is evaluating LAGEVRIO for post-exposure prophylaxis. To obtain an approval, we're collaborating with the European Medicines Agency to supply further data from these studies. Our confidence in LAGEVRIO's safety and efficacy for suitable patients has not wavered. Specifically, we think its low propensity for drug-drug interactions positions it as a valuable choice for patients. Turning now to our pneumococcal programs. The FDA this month extended the PDUFA date to July 1, 2022, for the supplemental biologics license application covering VAXNEUVANCE, our 15-valent conjugate pneumococcal vaccine for infants and children. Additional data analyses were asked for by the agency, and we supplied them. Crucially, no new studies were requested. Within our pneumococcal program as well, we obtained breakthrough therapy designation for V116, our investigational PCV designed to target serotypes responsible for roughly 80% of residual invasive disease among older adults, and it contains 8 unique serotypes absent from currently licensed vaccine; we anticipate sharing future updates. To close, I want to thank Roy Baynes for all he has contributed to Merck across the past 8 years. As we carry forward his legacy, I'm often reminded of Roy's business wisdom and teaching, and I feel fortunate to work alongside an outstanding team that he trained and mentored. Eliav Barr is, naturally, one of those mentees. Given Eliav's experience and dedication to Merck's purpose of saving and improving lives, he is the perfect person to lead our global clinical development program. Eliav brings a wealth of experience, having held leadership roles spanning an array of therapeutic areas throughout his 27 years at Merck, including vaccine, infectious disease and oncology. I'm eager to keep partnering with Eliav to extend Merck's legacy of innovation and breakthrough science. And now back to Peter.
Peter Dannenbaum
executiveThank you, Dean. Grace, if you could please begin the Q&A. <<operator_script>> Thank you.
Carter Gould
analystEdward here, filling in for Carter. We'd like to inquire about GARDASIL. Could you discuss whatever effects you're observing in China, whether from a demand standpoint or manufacturing interruptions? And with that in mind, should we consider the cadence — or should we consider the cadence across the year being markedly different from prior years? There are simply numerous variables at play. So any insight on that would be useful.
Caroline Litchfield
executiveCarter, it's Caroline speaking. Many thanks for asking. GARDASIL remains a tremendous growth engine for our organization worldwide, China included. Regarding China specifically, we delivered robust results during the quarter, and we anticipate that robust results will continue throughout this year. Demand in China is substantial. And since they're off-play owing to COVID and possibly a lockdown in a single region of the nation, we possess the capability to make sure we're delivering additional GARDASIL doses into other regions of the nation. Consequently, we do not foresee a meaningful effect on our GARDASIL results in China stemming from what we're witnessing in Shanghai right now. When it comes to our supply chain, our organization maintains a highly resilient supply chain; and we have plan A alongside plan B, should any supply chain disruptions occur; so once more, we hold no worries regarding our supply chain's dependability, yet we stay watchful and concentrated on the current circumstances.
Mohit Bansal
analystCongrats on the quarter. Something that keeps coming up from folks is your take on a potential competitive risk, or when it comes to the PD-L1 plus TIGIT pairing, which could appear better than KEYTRUDA for first-line PD-L1-high lung cancer. Does that strike you as a serious threat, especially considering the Phase II results from that rival's TIGIT?
Dean Li
executiveAppreciate the question. I'd like to emphasize that what's being asked is really about layering one more checkpoint inhibitor, TIGIT, onto PD-1. The idea behind that strategy is, in a sense, to make the PD-1 and PD-L1 response deeper. Looking at those results and breaking down what each component adds is going to matter a great deal. On our side, there's also a TIGIT program we're moving forward in non-small cell lung cancer as well as small lung cancer. As more data comes in, the lung community will need to figure out how much benefit TIGIT brings on top of PD-1. That said, I'd like to step back and note something bigger: you're going to keep seeing shifts around TIGIT, and not long ago there were similar shifts involving PD-1 and CTLA-4, PD-1s, and LAG-3. When you look at each of these pairings, the way they work is that proving an added agent helps doesn't carry the wide-ranging effect that PD-1 demonstrates across numerous cancers. That's why I feel it's worth stressing that we aren't putting all our effort solely into LAG-3, nor solely into CTLA-4, nor solely into TIGIT — instead we're backing all 3 and aiming each at particular kinds of tumors.
Seamus Fernandez
analystI'd like to zero in on sotatercept and the 6-minute walk test as the primary endpoint. Could you help us grasp what's being carried out in the clinical trial to tightly control the risk that a somewhat subjective endpoint like this introduces? Or do you feel confident that the size of the difference observed in the Phase II will easily overcome the difficulties with the 6-minute walk test that we've witnessed in certain other studies, given some placebo responses that heightened concern? I'd really appreciate your perspective on that.
Dean Li
executiveYes. Thank you very much for that question regarding sotatercept; to restate it, we have 3 separate trials, each aiming at somewhat distinct outcomes, the 6-minute walk, which is the STELLAR trial. There's also time to clinical worsening, and beyond that there are even tougher outcomes. As you mention, every one of those is progressively raising the bar for what sotatercept might achieve. Regarding the first, STELLAR, tied to what you brought up, the 6-minute walk test, where we actually observed fairly striking data in connection with the Phase II. We have highly dedicated patient groups along with sites that are extremely well trained in conducting these trials; and the Phase II data was really encouraging; and the core point is that we're confident many of those identical sites that took part in the Phase II are taking part in Phase III. So I believe we're confident we'll find out what that data shows. But the strongest predictor of how effectively we can run those trials is truly the strongest signal, which is the Phase II, and we're relying there on many of the same sites and the investigators; so our confidence in them is high.
Chris Schott
analystPerhaps I'll ask two things tied to the corporate structure topic. First, on the business development landscape — I realize you've described this as a priority. I believe we've just been through yet another quarter where equity market performance was weak on the biotech side; so, have you noticed any shift in how willing some targets are to engage, or any valuation resets that might let some of these business development activities go ahead? Then Rob, a somewhat related question on that: across the pharma group generally, I think we've been observing divestitures of assets in nontraditional pharma businesses. I realize you've regarded Animal Health as more central to the company. I'm curious whether your perspective has evolved during your time leading the company, particularly when you weigh the core pharma value the market is implying for you against the multiples that some animal health businesses are getting. If you have anything to add on that, we'd appreciate it.
Rob Davis
executiveThanks, Chris, for raising those points. On the business development landscape, the short version is that seller expectations haven't moved in any fundamental way as far as we can tell. My sense is that if the market correction turns out to be longer lasting, and especially if biotech companies keep finding the IPO window difficult, that could change things down the road as those companies find themselves with tighter cash positions. Certain of the smaller participants are indeed dealing with cash pressure. That's probably the area where we'd see a shift happen before anywhere else. Still, when you get right down to it, nothing about the broader picture has really shifted at this point. It's a matter of continuing to monitor things. Turning to Animal Health, our position hasn't changed — that business, like you mentioned, sits at the heart of this company. It's central to how we're pursuing growth, acting as one of the engines driving us forward. That said, as we've consistently noted, we review it on a routine basis. We're constantly pushing ourselves to weigh what sort of value this business can generate over the long haul under our ownership against what it might generate if it sat somewhere else. And looking out over the long term, our belief holds that keeping it inside the company is the better path. If things change, though, we'll keep assessing it without bias, as we always do. Still, our focus isn't on near-term arbitrage gains. What matters to us is building value over the long haul, and so far that approach remains the same.
Chris Shibutani
analystCould I ask about KEYTRUDA, and specifically how strong it was outside the U.S. during this quarter? It would help if you could walk us through a few of the drivers behind that. And on a connected note, over the longer horizon, 2025 — I believe you laid out how, for KEYTRUDA, your aim is to have — I think the phrasing shifted a bit. Before, you were targeting 30% from adjuvant, with your emphasis described in terms of the U.S. If I understand it right, you've now moved that framework to thinking about 25% on a worldwide basis. Perhaps you could tell us where you believe you stand when it comes to advancing toward those goals for the adjuvant revenue contribution.
Rob Davis
executiveYes. So Chris, it's Rob here. Perhaps I'll handle the first portion of your question, and then Caroline can come in on the second portion. Regarding how strongly we're growing in the United States, that really demonstrates what we've said from the beginning, namely that as we keep launching additional indications, our share keeps expanding as the top I-O agent. And what's more, I'd point out that the growth we recorded this quarter included, among other things, our ongoing position in renal cell carcinoma and our ongoing growth in head and neck; in RCC, clearly, as a first-line treatment in the metastatic setting and now with adjuvant therapy too, we've essentially addressed every part of RCC, and there's room for us to keep growing there. Yet the real standout for the quarter, and I think this matters a great deal to grasp, is triple-negative breast cancer, in the metastatic setting and the adjuvant setting alike. We're witnessing tremendous growth in that area, and it's something we take a lot of pride in, since I believe we will make a meaningful difference there. The reason I call that out is that both — when you consider the adjuvant opportunity in that setting and the growth we're achieving, plus, as I said, in adjuvant RCC, I think it simply confirms what we view as the future, namely the contribution to growth that will come from earlier lines of therapy over the long term. With that, perhaps Caroline can speak to some of the guidance we've given.
Caroline Litchfield
executiveRegarding what Rob brought up, the chance we have with adjuvant therapy and the difference it makes for patients is something we feel tremendous enthusiasm about. At the outset, we communicated our expectation that adjuvant would account for 50% of our growth, which would equal 30% of the U.S. business. Our updated position is that 50% of growth will be driven by adjuvant, making up 25% of our global business in the year 2025. And as Rob mentioned, entering earlier-stage cancers sooner, with 5 indications in KEYTRUDA at this point, is setting us up well to achieve that effect.
Umer Raffat
analystLet me quickly bring up molnupiravir. As of mid-April, roughly 200,000 courses have been utilized in total, I believe. And from what third-party data sets indicate, at minimum, the Pfizer regimen is being prescribed 8 to 10x as often as molnupiravir. So my question is this: given that just a couple hundred thousand courses were used through mid-April, while 3.1 million courses were contracted to the U.S., can the U.S. return any portion of those courses? I ask because a number of these sales have already been booked in P&L. I simply want to confirm that those sales are permanent.
Rob Davis
executiveYes. I'll let Caroline perhaps take that one.
Caroline Litchfield
executiveUmer, I appreciate that question. Let me begin by saying that molnupiravir, or LAGEVRIO, is something we take pride in, along with the difference it can make worldwide; it also carries significance for the remarks Dean offered, particularly for patients dealing with drug-to-drug interactions. According to the data available to us, roughly 500,000 patients around the globe have used it so far. To date, we have shipped 6.4 million courses. Those shipment figures reflect anticipated usage across a stretch of time. What we are witnessing is remarkably robust uptake, above all outside the U.S., where in certain markets the statistics you cite are in fact flipped. Our market share is quite strong. So, as of today, we have provided guidance of $5 billion to $5.5 billion, grounded in the contracts already secured, and we feel assured about that within our financials.
Daina Graybosch
analystI've got a second question about KEYTRUDA in the earlier setting. Could you discuss how Opdivo's positive result combined with chemo in neoadjuvant lung cancer alters what you expect, or your approach, for early-stage chances both in lung cancer and then in that other tumor type?
Dean Li
executiveSure. I appreciate you asking that. When it comes to the earlier stage of lung cancer, I want to stress something: there are multiple distinct ways to go after this. Neoadjuvant plus adjuvant is one. Adjuvant alone is another. And I believe every one of these signals simply shows, across a range of different trials, the effect that PD-1s are capable of having. From where we sit, this ought not to alter our approach; it ought to make our approach quite thorough. The key fact is we have KEYNOTE-091, which sits in the adjuvant setting — meaning after surgery — and a medical oncologist typically administers it. Disease-free survival came out positive in all-comers no matter the PD-L1 status. A trend appeared for TPS above 50%, though it wasn't statistically significant. As for OS, a favorable trend showed up regardless of PD-L1. So we'll let those data mature while we keep talking with the FDA. But to get to what you raised, it isn't only KEYNOTE-091; there's also KEYNOTE-671, KEYNOTE-867, and KEYLYNK-012. Each of these is in the earlier stage. So our wish to genuinely advance that earlier stage will be — if anything, our dedication to it has only grown stronger. One more thing I'd mention, tied to remarks Caroline and Rob offered: I believe it's crucial to consider melanoma, renal cell carcinoma, and triple-negative breast cancer, where — at least from my time working in the hospital — there's this notion of truly examining that earlier stage. And I suspect uptake might be somewhat inherent to the medical system. I think everyone, ourselves included, along with other companies, patient advocacies, and medical centers, will need to put in diligent investment to truly, truly maximize the significant scientific effects of KEYTRUDA and PD-1s and PD-L1s in the early lung space.
Andrew Baum
analystI want to express my gratitude to Roy for everything he has contributed and the insights he has shared throughout the years. My question concerns your Factor XI monoclonal. Considering your cardiology experience, and I'm certain you maintain familiarity with the hemostasis team. There have clearly been several indications in which DOACs did not succeed relative to warfarin regarding both efficacy and safety, possibly pointing to distinct underlying mechanisms for thrombosis and a different indication as I consider ESS, I'm considering mechanical heart valves. When you think about Factor XI biology and how the intrinsic pathway gets inhibited, are there any indications where you'd choose not to go, or where you'd want to be especially careful about introducing a Factor XI inhibitor—whether it's yours or a different company's?
Dean Li
executiveYeah, let me briefly pull back for a moment. Right now, the question of benefit-risk for anything touching platelets or coagulation factors in the context of clotting is truly a hot topic in the news. I'd just point out that aspirin was absolutely ubiquitous for years—probably ten years or more. And more recently, once people came to understand the benefit-risk, you have to be very cautious. The rules have shifted significantly, which changes my perspective on this. Another factor to consider is that with Factor XI, the key benefit lies in being able to block the coagulation cascade while—based on genetic evidence—having minimal associated side effects. For me, the most important priority is to demonstrate that as fast as we can. So we go straight to the area of greatest concern, where both clotting and bleeding are problems; that's the reason we conducted the trial in end-stage renal disease. However, looking ahead, I can envision mechanical devices—one that I'm particularly fond of is the left ventricular assist device. That's something we'll have to keep watching going forward. The danger of hemorrhage and the danger of clot formation are both extremely elevated in that context. One area where we've deliberately held back a bit involves broader conditions—things like atrial fibrillation and how it ties to stroke risk—since we regard Factor X as highly efficacious. Bleeding issues do occur, yet building a safety case around that would demand an enormous study. So instead, we're moving quickly toward situations involving the tradeoff between clotting benefits and bleeding harms, where that gap would let something like Factor XI deliver its greatest effect.
Louise Chen
analystI'd like to ask about your pneumococcal conjugate vaccine. How do you figure that a more targeted strategy gives you an edge over the one-size-fits-all situation we currently see? Also, does anything that came before support what you're doing with V116 and 117? And then perhaps finally, given that if all goes according to plan you'll have multiple PCVs on the market, how do you get that message across clearly to physicians?
Dean Li
executiveYes. To start, we have to obtain the data showing we hold an advantage across the various patient populations. That said, I believe you're raising a truly significant point, which is basically that what we're attempting to accomplish is — for want of a better term — you could label it precision-targeted vaccinations, correct? So the core fact is V114 holds adult approval, and we're pushing toward pediatric approval for the 15-valent. That therefore will be in the pediatric population. With V116, for which we hold a breakthrough designation, we're working to show we can address 85% of the residual serotypes. And I'd simply note it would be 8 unique serotypes relative to all the various ones approved at present. And regarding that patient population, I think a bit about COVID, but it's the older group, particularly those carrying the risk factors, where you truly want to ensure that the entire population, that adult population, is covered. So I do believe the core fact is we'll need the data, yet our concept is that adults carry a distinct set of serotypes and require protection, and we'll need the data to show that. But I think if we can show it, uptake will be rather strong.
Mara Goldstein
analystI'd like to circle back, if we could, to the topic of new targets being paired with KEYTRUDA. Perhaps you could offer us a big-picture view — maybe the rationale — behind the targets you're pursuing and the indications involved. Clearly, I'm talking about agents such as TIGIT, LAG-3, ILT3, and similar ones.
Dean Li
executiveSure. Let me break that apart a bit. Our framework is always expand, deepen, and extend. When we discuss deepening, the goal is achieving a stronger response using PD-1s. There's a set of approaches we take involving what I'd term non-I-O agents — that means chemotherapy. We're working with numerous other parties, plus on our own, with ADCs. Our RAS programs keep moving forward. So with that kind of combination, we already have substantial precedent across our portfolio, and that will keep growing. The same holds for Lenvima and Lynparza. The particular thing you're getting at, I believe, is pairing I-O with I-O agents — LAG-3, CTLA-4, and TIGIT. In our thinking, at least, we do acknowledge there was evidence showing LAG-3 added something to PD-1 in melanoma. That's a meaningful signal in our view. Our LAG-3 effort has concentrated on MSS CRC. We're aware PD-1s are effective in MSI-high, yet nobody has truly managed to crack MSS CRC. That matters a great deal, and classic Hodgkin's as well. Regarding CTLA-4, recent data emerged with HCC. I'd add a remark that might bring a smile to a few folks at Merck. We were actually the ones who ran the study of PD-1 plus CTLA-4 in lung. We couldn't demonstrate a clear contribution from the CTLA-4 component beyond PD-1. So that isn't somewhere we see as important for patients, and it isn't somewhere we're heading, since we ran that study precisely to show that. Where we believe opportunity exists is — plainly, others have recently put out HCC data. We're concentrating, for instance, on renal cell carcinoma. Then for PD-1 and TIGIT, our early focus is non-small cell lung cancer, plus small cell lung cancer. We're pushing forward a set of trials there. So I hope that provided a thorough picture regarding LAG-3, CTLA-4, and TIGIT. As for ILT4, other checkpoint inhibitors like CD27, or cytokines, I believe the earlier-stage data we're generating will need to mature before we can address that fully.
Peter Dannenbaum
executiveAll right. Thanks, Mara. I believe there's room for one additional question, and then Rob is going to offer some final remarks.
Colin Bristow
analystNice work on the quarter. I'd also like to wish Roy all the best; working alongside you has truly been a pleasure, and congratulations to Eliav as well; I just want to follow up on a GARDASIL question. Could you perhaps share a bit more about how you see GARDASIL supply ramping up? And then maybe walk us through what the supply/demand imbalance looks like at present? A few of your earlier remarks implied there might not be one; yet I recall you mentioning that supply has been problematic across roughly the last 2 years; so I'd appreciate some broader perspective on that.
Caroline Litchfield
executiveThanks for asking; Caroline here. Let me begin with supply/demand. Demand for GARDASIL is substantial; this vaccine that prevents cancer in the HPV space has so far reached just 9% of those eligible worldwide. That leaves a considerable path in front of us to safeguard lives and generate growth for Merck. As a matter of fact, we've said we anticipate revenue for 2030 reaching twice the $5.7 billion recorded in 2021. So a major opportunity lies before us. To capture that opportunity, we're constructing new facilities set to come online starting in 2023, 2024 and 2025. As a result, we'll see an increase in the amount of supply reaching the market across that stretch. Turning specifically to this year, supply to the market will keep flowing much as it did in 2021, though not with quite the same step-up we saw in 2021. So we stay very confident about our capacity to deliver robust growth for GARDASIL in 2022 and beyond.
Peter Dannenbaum
executiveGreat. Thank you, Colin. Rob?
Rob Davis
executiveWell, I want to express my appreciation for the time you've given us and the interest you've shown today. To wrap up, I'd like once more to thank the Merck team around the world for their dedication and focus, and truly for producing the results that have been described to you today, but also for continuing to make sure we keep the company's purpose at the very center, which is delivering for patients. I hope you're getting the impression that our confidence in the momentum of this business is very high. And I'd add that our feelings keep improving regarding how our pipeline is developing, and based on what's been presented to you today, we're beginning to grow; we're carrying out everything necessary. There's still more work ahead of us, but our progress has been substantial. That's the reason my confidence is so strong regarding the long-term durability of this business. So we're eager to keep sharing these results with you, to deliver for the patients who depend on us and, in turn, create value for the shareholders; so with that, I'll say thank you and have a wonderful day.
Operator
operatorThanks a lot, presenters. That wraps up the conference call for today. I appreciate everyone for being on the line. At this point, you're all free to hang up.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.